Rapport Therapeutics Q3 2026 earnings
Net loss widened to $56.6 million as R&D expenses increased to $51.4 million, though cash position remained strong at $436.1 million.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| EPS (GAAP) | -$1.19 | +59% | — | Ex. 99.1, income statement |
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin not stated in the 8-K
- Operating expenses $60.8 million (+106% YoY)
- One-offs in the quarter not stated in the 8-K
- Effective tax rate not stated in the 8-K
- Non-GAAP bridge not stated in the 8-K
KPIs
not stated in the 8-K
Guidance
not stated in the 8-K
What drove it
- Revenue story No revenue reported; company is clinical-stage.
- EPS story Net loss per share widened to -$1.19 driven by higher operating expenses.
- One-off check not stated in the 8-K
The good
- Cash position of $436.1 million expected to fund operations into the second half of 2029
The bad
- Net loss widened to $56.6 million (+112% YoY)
- R&D expenses increased to $51.4 million (+127% YoY)
- SG&A expenses increased to $9.4 million (+38% YoY)
The ugly
- none
Open questions
- No Q3 financial results were provided in the filing; only a business update was attached.
Full release
Rapport Therapeutics (RAPP) earnings release, October 30, 2026
No press release attached to this 8-K.